Some of the commonly identified mutations associated with targeted therapies include, e.g., mutations in BRAF in cutaneous melanoma; KRAS, BRAF, and NRAS in colorectal cancer; and EGFR mutations and ALK and ROS1 gene rearrangements in lung adenocarcinomas [2,3,4]. This evidence concerns the gene KRAS and lung adenocarcinoma.